The safety and efficacy of full-versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial

APEX Investigators, I. Stukena (Member of the Working Group)

Research output: Contribution to journal › Article › peer-review

48 Citations (Scopus)

Fingerprint

Dive into the research topics of 'The safety and efficacy of full-versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science